{
    "clinical_study": {
        "@rank": "100913", 
        "arm_group": [
            {
                "arm_group_label": "Subjects with renal impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Subjects with normal renal function", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of\n      oral semaglutide in subjects with various degrees of impaired renal function compared to\n      subjects with normal renal function."
        }, 
        "brief_title": "Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 18-85 years (both inclusive) at the time of signing inform\n             consent\n\n          -  Subject with normal renal function or renal impairment (mild, moderate, severe or\n             end-stage renal disease requiring dialysis)\n\n          -  For subject with normal renal function: good general health (as judged by the\n             investigator)\n\n          -  Body mass index (BMI) 18.5-40.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of\n             child-bearing potential and not using adequate contraceptive methods\n\n          -  History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease\n\n          -  Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180\n             mmHg and/or diastolic blood pressure above or equal to 100 mmHg)\n\n          -  Any blood draw or donation of blood or plasma in excess of 400 mL within the 3 months\n             preceding the screening visit (Visit 2)\n\n          -  History of significant drug abuse, or a positive drug test at the screening visit\n             (Visit 2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014259", 
            "org_study_id": "NN9924-4079", 
            "secondary_id": [
                "2013-000682-36", 
                "U1111-1139-4281"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Subjects with renal impairment", 
                "Subjects with normal renal function"
            ], 
            "description": "Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg", 
            "intervention_name": "semaglutide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 10, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Praha 7", 
                        "country": "Czech Republic", 
                        "zip": "17000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1115"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Czech Republic: State Institute for Drug Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the semaglutide plasma concentration time curve", 
            "safety_issue": "No", 
            "time_frame": "From time 0 to 24 hours after the 10th dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed semaglutide plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours after the 10th dosing"
            }, 
            {
                "measure": "Area under the SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate /salcaprozate sodium) plasma concentration time curve", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours after the 10th dosing"
            }, 
            {
                "measure": "Maximum observed SNAC plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours after the 10th dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}